AVR Anteris Technologies Global Corp.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 2011514 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.0%
TTM net income YoY-28.3%
TTM EPS YoY36.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin75.8%
Operating margin-4,880.4%
Net margin-4,637.5%
FCF margin-4,008.4%
EBITDA margin-4,802.4%
Returns
ROE-93.8%
ROA-76.8%
ROIC (approx.)-3,856.3%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets13.5%
Debt / equity0.00x
Current ratio12.45x
Interest coverage-615.19x
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-12.3%
Payout ratio—
Capex / revenue110.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $519,000 | $1.01M | $494,000 | $310,000 | $429,000 | $618,000 | $556,000 | $536,000 |
| Cost of revenue | $126,000 | $233,000 | $114,000 | $91,000 | $123,000 | $148,000 | $207,000 | $208,000 |
| Gross profit | $393,000 | $776,000 | $380,000 | $219,000 | $306,000 | $470,000 | $349,000 | $328,000 |
| R&D expense | $21.33M | $23.37M | $17.46M | $19.51M | $16.81M | $16.34M | $16.46M | $13.32M |
| SG&A expense | $8.90M | $8.40M | $6.93M | $9.67M | $5.76M | $5.01M | $5.67M | $8.53M |
| Operating income | -$29.84M | -$31.00M | -$24.01M | -$28.96M | -$22.27M | -$20.88M | -$21.78M | -$21.52M |
| Interest expense | $17,000 | $131,000 | $27,000 | $10,000 | $15,000 | $22,000 | $26,000 | $8,000 |
| Pretax income | -$27.10M | -$28.78M | -$22.41M | -$29.02M | -$22.21M | -$21.06M | -$21.93M | -$19.20M |
| Income tax | -$272,000 | $0 | $492,000 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$26.83M | -$29.09M | -$23.02M | -$29.20M | -$22.24M | -$20.83M | -$21.86M | -$19.38M |
| EBITDA | -$29.34M | -$30.53M | -$23.58M | -$28.54M | -$21.85M | -$20.47M | -$21.38M | -$21.11M |
| EPS (basic) | -0.28 | -0.30 | -0.28 | — | -0.62 | -0.58 | -0.61 | — |
| EPS (diluted) | -0.28 | -0.30 | -0.28 | — | -0.62 | -0.58 | -0.61 | — |
| Weighted avg. shares (diluted) | 97.46M | 97.34M | 83.01M | — | 36.06M | 36.06M | 36.01M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $216.99M | $249.90M | $283.21M | $6.70M | $9.12M | $28.44M | $48.95M | $70.46M |
| Receivables | $220,000 | $548,000 | $231,000 | $32,000 | $234,000 | $687,000 | $189,000 | $208,000 |
| Inventory | $0 | $8,000 | $122,000 | $152,000 | $436,000 | $449,000 | $364,000 | $513,000 |
| Current assets | $237.58M | $260.65M | $286.67M | $15.68M | $11.22M | $32.21M | $52.98M | $74.65M |
| PP&E, net | $5.68M | $5.62M | $5.18M | $5.26M | $5.29M | $4.93M | $4.66M | $4.77M |
| Intangibles | $89,000 | $97,000 | $105,000 | $65,000 | $70,000 | $98,000 | $142,000 | $189,000 |
| Total assets | $262.46M | $272.51M | $294.72M | $23.00M | $19.07M | $39.88M | $58.79M | $80.70M |
| Current liabilities | $19.09M | $18.36M | $13.69M | $21.37M | $13.43M | $13.34M | $14.43M | $16.56M |
| Short-term debt | $117,000 | $404,000 | $707,000 | $16,000 | $96,000 | $387,000 | $690,000 | $3,000 |
| Long-term debt | $61,000 | $47,000 | $18,000 | $22,000 | $26,000 | $30,000 | $30,000 | $0 |
| Total debt | $178,000 | $451,000 | $725,000 | $38,000 | $122,000 | $417,000 | $720,000 | $3,000 |
| Total liabilities | $35.41M | $20.84M | $16.31M | $23.25M | $15.71M | $15.85M | $15.68M | $18.02M |
| Shareholders' equity | $226.77M | $251.39M | $278.44M | -$93,000 | $3.70M | $24.41M | $43.26M | $62.76M |
| Net debt | -$216.81M | -$249.45M | -$282.49M | -$6.66M | -$9.00M | -$28.02M | -$48.23M | -$70.45M |
| Shares outstanding | 97.49M | 97.41M | 97.23M | 41.58M | 36.06M | 36.06M | 36.06M | 35.94M |
| Cash flow statement | ||||||||
| Operating cash flow | -$22.90M | -$20.80M | -$28.68M | -$18.53M | -$18.25M | -$19.54M | -$21.49M | -$18.24M |
| Capital expenditure | $1.40M | $648,000 | $137,000 | $397,000 | $772,000 | $537,000 | $248,000 | $363,000 |
| Free cash flow | -$24.29M | -$21.45M | -$28.82M | -$18.92M | -$19.02M | -$20.07M | -$21.74M | -$18.60M |
| Investing cash flow | -$1.40M | -$648,000 | -$182,000 | -$397,000 | -$772,000 | -$537,000 | $1.11M | -$364,000 |
| Financing cash flow | -$264,000 | -$877,000 | $299.51M | $22.38M | -$294,000 | -$442,000 | -$1.09M | $78.40M |
| Depreciation & amortization | $496,000 | $469,000 | $429,000 | $423,000 | $417,000 | $418,000 | $403,000 | $404,000 |
| Stock-based compensation | $1.40M | $3.98M | $1.82M | $3.03M | $1.60M | $1.58M | $1.70M | $1.30M |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.